Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial

Cancer Group ◽

Group 12 ◽

Risk Prostate Cancer ◽

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial

European Urology ◽

10.1016/j.eururo.2018.01.012 ◽

2018 ◽

Vol 73 (6) ◽

pp. 870-876 ◽

Cited By ~ 22

Author(s):

Göran M. Ahlgren ◽

Per Flodgren ◽

Teuvo L.J. Tammela ◽

Pirkko Kellokumpu-Lehtinen ◽

Michael Borre ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Open Label ◽

Phase 3 ◽

Cancer Group ◽

Group 12 ◽

Risk Prostate Cancer ◽

ZOLEDRONIC ACID FOR THE PREVENTION OF BONE METASTASES IN HIGH RISK PROSTATE CANCER PATIENTS. A RANDOMISED, OPEN LABEL, MULTICENTRE STUDY OF THE EUROPEAN ASSOCIATION OF UROLOGY (EAU) IN COOPERATION WITH THE SCANDINAVIAN PROSTATE CANCER GROUP (SPCG) AND THE ARBEITSGEMEINSCHAFT UROLOGISCHE ONKOLOGIE (AUO)

European Urology Supplements ◽

10.1016/s1569-9056(08)60644-2 ◽

2008 ◽

Vol 7 (3) ◽

pp. 232 ◽

Cited By ~ 2

Author(s):

M. Wirth ◽

T. Tammela ◽

H. Huland ◽

V. Cicalese ◽

F. Gomez Veiga ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

High Risk ◽

Multicentre Study ◽

European Association ◽

Open Label ◽

Cancer Group ◽

Risk Prostate Cancer ◽

European Association Of Urology

Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.040

European Urology ◽

10.1016/j.eururo.2021.02.024 ◽

2021 ◽

Author(s):

Alberto Briganti ◽

Giorgio Gandaglia ◽

Markus Graefen ◽

Steven Joniau ◽

R. Jeffrey Karnes ◽

...

Keyword(s):

Prostate Cancer ◽

Lymph Node ◽

High Risk ◽

Radical Prostatectomy ◽

Pelvic Lymph Node Dissection ◽

Node Dissection ◽

Phase 3 ◽

Oncological Outcomes ◽

715 EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF BONE METASTASES IN HIGH RISK PROSTATE CANCER PATIENTS. A RANDOMISED, OPEN LABEL, MULTICENTER STUDY OF THE EUROPEAN ASSOCIATION OF UROLOGY (EAU) IN COOPERATION WITH THE SCANDINAVIAN PROSTATE CANCER GROUP (SPCG) AND THE ARBEITSGEMEINSCHAFT UROLOGISCHE ONKOLOGIE (AUO). A FIRST REPORT OF THE “ZEUS” STUDY

European Urology Supplements ◽

10.1016/s1569-9056(07)60711-8 ◽

2007 ◽

Vol 6 (2) ◽

pp. 201 ◽

Cited By ~ 1

Author(s):

M.P. Wirth ◽

T. Tarmimela ◽

W. Witjes

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

High Risk ◽

Cancer Patients ◽

European Association ◽

Open Label ◽

Cancer Group ◽

Risk Prostate Cancer ◽

European Association Of Urology

Extended vs Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3426082 ◽

2019 ◽

Author(s):

Jean Lestingi ◽

Giuliano Betoni Guglielmetti ◽

Quoc-Dien Trinh ◽

Rafael Ferreira Coelho ◽

Jose Pontes, Jr ◽

...

Keyword(s):

Prostate Cancer ◽

Lymph Node ◽

High Risk ◽

Radical Prostatectomy ◽

Pelvic Lymph Node Dissection ◽

Node Dissection ◽

Phase 3 ◽

Oncological Outcomes ◽

Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients: a randomised, open-label, multicentre study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO)

http://isrctn.org/> ◽

10.1186/isrctn66626762 ◽

2012 ◽

Author(s):

W. de Bruijn

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Multicentre Study ◽

Cancer Patients ◽

European Association ◽

Open Label ◽

Cancer Group ◽

Risk Prostate Cancer ◽

European Association Of Urology

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

European Urology ◽

10.1016/j.eururo.2019.08.010 ◽

2019 ◽

Vol 76 (6) ◽

pp. 823-830 ◽

Cited By ~ 2

Author(s):

Pirkko-Liisa Kellokumpu-Lehtinen ◽

Marie Hjälm-Eriksson ◽

Camilla Thellenberg-Karlsson ◽

Lennart Åström ◽

Lars Franzen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Radical Radiotherapy ◽

Open Label ◽

Risk Prostate Cancer ◽

Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (Sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy

Current Urology Reports ◽

10.1007/s11934-007-0014-8 ◽

2007 ◽

Vol 8 (1) ◽

pp. 3-4 ◽

Cited By ~ 4

Author(s):

Allan J. Pantuck ◽

Nazy Zomorodian ◽

Arie S. Belldegrun

Keyword(s):

Prostate Cancer ◽

Clinical Study ◽

High Risk ◽

Radical Prostatectomy ◽

Phase I ◽

Multiple Dose ◽

Single Center ◽

Open Label ◽

Corrigendum re “Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial” [Eur Urol 2019;76:823–30]

European Urology ◽

10.1016/j.eururo.2020.08.035 ◽

2020 ◽

Vol 78 (6) ◽

pp. e241-e242

Author(s):

Pirkko-Liisa Kellokumpu-Lehtinen ◽

Marie Hjälm-Eriksson ◽

Camilla Thellenberg-Karlsson ◽

Lennat Åström ◽

Lars Franzen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Radical Radiotherapy ◽

Open Label ◽

Risk Prostate Cancer ◽

Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial

European Urology ◽

10.1016/j.eururo.2020.11.040 ◽

2020 ◽

Author(s):

Jean F.P. Lestingi ◽

Giuliano B. Guglielmetti ◽

Quoc-Dien Trinh ◽

Rafael F. Coelho ◽

Jose Pontes ◽

...

Keyword(s):

Prostate Cancer ◽

Lymph Node ◽

High Risk ◽

Radical Prostatectomy ◽

Pelvic Lymph Node Dissection ◽

Node Dissection ◽

Phase 3 ◽

Oncological Outcomes ◽